Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Thyrocare Technologies's Debt-to-EBITDA or its related term are showing as below:
NSE:THYROCARE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 0.29
Current: 0.17
During the past 13 years, the highest Debt-to-EBITDA Ratio of Thyrocare Technologies was 0.29. The lowest was 0.02. And the median was 0.08.
NSE:THYROCARE's Debt-to-EBITDA is ranked better than 91.45% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.52
vs NSE:THYROCARE: 0.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Thyrocare Technologies Debt-to-EBITDA Related Terms
Thyrocare Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Thyrocare Technologies (NSE:THYROCARE) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thyrocare Technologies. Over the past decade, Thyrocare Technologies' Debt-to-EBITDA has ranged from 0.02 to 0.29. According to the industry distribution chart, Thyrocare Technologies ranks #10 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is Thyrocare Technologies' Debt-to-EBITDA too high?
Thyrocare Technologies' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.29. Based on the distribution chart, Thyrocare Technologies ranks #10 out of 117 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #10 out of 117 companies for Debt-to-EBITDA. This places Thyrocare Technologies in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.52. Historically, Thyrocare Technologies' own Debt-to-EBITDA has ranged from 0.02 to 0.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.52, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thyrocare Technologies. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹429.45, compared to a current price of ₹549.70 — trading 28% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Thyrocare Technologies' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹549.70 is trading 28% above its estimated GF Value™ of ₹429.45.
GuruFocus considers Thyrocare Technologies to be Modestly Overvalued.
Key valuation signals for NSE:THYROCARE:
Debt-to-EBITDA: 0.00
GF Value™: ₹429.45 vs. price of ₹549.70 (28% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
83GF Score
Get the complete analysis for NSE:THYROCARE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
